The less‐known face of dupilumab: its role in mesenchymal stem cells by interleukin‐13 modulation

Abstract

reduction of 52Á8% (range 28Á2-83Á7). All 20 patients were responders and 12 (60%) achieved a Sartorius score improvement ≥ 50%.The mean number of exacerbations was 3Á6 (range 1Á0-10Á0) in the 3 months before the treatment and 2Á0 (range 0-8Á0) at T1, corresponding to a mean reduction of 37Á1% (range 0-100). Both Sartorius score and the number of exacerbations showed a significant reduction after treatment (P = 0Á001 for Sartorius score and P = 0Á001 for the number of exacerbations).Three of 20 patients (15%) reported mild gastrointestinal side-effects (gastric pain, nausea or diarrhoea) not related to Clostridium difficile colitis. For two of three patients with sideeffects, treatment was temporarily suspended for 4 days; in spite of this, all 20 patients completed 10 weeks of treatment.Our study has some limitations. We did not include data about long-term follow-up and we did not analyse the efficacy of the treatment after the end of the study. Moreover, this was a pilot study with a small sample size. It was not possible to establish with statistical power which were the predictive indicators of nonresponse to treatment, in correlation to the demographic data (sex, age of onset, duration of disease, Hurley stage, BMI, smoking and family history). The efficacy and tolerability of this combination treatment in HS-AI has previously been assessed in three retrospective studies and one prospective study. [4][5][6][7] To the best of our knowledge, the present study is the first to examine a cohort of paediatric patients, and the results are in agreement with those previously reported in the literature. This study demonstrates that rifampicin in association with clindamycin is a good option for the treatment of active inflammatory HS-AI in paediatric patients in terms of efficacy, tolerability, quick onset of action and limited cost of therapy.

miRNAs, Mesenchymal Stromal Cells and Major Neoplastic and Inflammatory Skin Diseases: A Page Being Written: A Systematic Review

“…MSCs are multipotent cells residing in multiple tissues with the capacity for selfrenewal and differentiation into various cell types [9,10]. Our previous works confirmed that different pathologies, ranging from the dermatologic to the fibrotic ones [11][12][13][14][15][16][17][18][19][20], arise at the staminal level: MSCs show the same dysregulated pathological properties found in differentiated cells, opening up the hypothesis that the onset of the diseases could be backdated at the stem level.…”

A Systematic Review of Atopic Dermatitis: The Intriguing Journey Starting from Physiopathology to Treatment, from Laboratory Bench to Bedside

“…Starting from these considerations, today, dealing with AD is more than “treating chronic eczema”. The therapeutic strategies available and those that will appear soon have the ambition to modify not only the clinical course but also the natural history of the disease, preventing the cumulative burden that the disease has on the lives of affected patients [ 71 , 72 ]. Understanding AD pathogenesis in depth may represent a starting point that is useful for understanding how the therapeutic panorama of AD is being enriched, through a “bench to bedside” journey [ 72 ].…”